Advertisement

Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial

  • Bee Kim Tan
  • Siew Siang Chua
  • Li-Chia Chen
  • Kian Meng Chang
  • Sharmini Balashanker
  • Ping Chong BeeEmail author
Original Article
  • 64 Downloads

Abstract

Purpose

Suboptimal adherence to tyrosine kinase inhibitors (TKIs) contributes to poor clinical outcomes in chronic myeloid leukemia (CML). This randomised controlled trial (RCT) aimed to evaluate the impact of a medication management service (MMS) on adherence to TKIs and clinical outcomes.

Methods

A parallel RCT was conducted in two hospitals in Malaysia, where 129 CML patients were randomised to MMS or control (usual care) groups using a stratified 1:1 block randomisation method. The 6-month MMS included three face-to-face medication use reviews, CML and TKI-related education, two follow-up telephone conversations, a printed information booklet and two adherence aids. Medication adherence (primary outcome), molecular responses and health-related quality of life (HRQoL) scores were assessed at baseline, 6th and 12th month. Medication adherence and HRQoL were assessed using medication possession ratio and the European Organisation for Research and Treatment in Cancer questionnaire (EORTC_QLQ30_CML24) respectively.

Results

The MMS group (n = 65) showed significantly higher adherence to TKIs than the control group (n = 64) at 6th month (81.5% vs 56.3%; p = 0.002), but not at 12th month (72.6% vs 60.3%; p = 0.147). In addition, a significantly higher proportion of participants in the MMS group achieved major molecular response at 6th month (58.5% vs 35.9%; p = 0.010), but not at 12th month (66.2% vs 51.6%; p = 0.092). Significant deep molecular response was also obtained at 12th month (24.6% vs 10.9%; p = 0.042). Six out of 20 subscales of EORTC-QLQ30-CML24 were significantly better in the MMS group.

Conclusions

The MMS improved CML patients’ adherence to TKI as well as achieved better clinical outcomes.

Trial Registration

Clinicaltrial.gov (ID: NCT03090477)

Keywords

Medication management service Adherence Molecular response Health-related quality-of-life Chronic myeloid leukaemia Tyrosine kinase inhibitors 

Notes

Acknowledgements

The authors express their gratitude to all patients who have participated in the study. We would also like to record our appreciation to all the staff in the haematology clinics of the two hospitals in this study for their cooperation and assistance. We are grateful to Associate Professor Karuthan A/L Chinna from Taylor’s University Malaysia for his advice on statistical analysis, and to EORTC Quality of Life Group for permission granted to use the EORTC_QLQ30_CML24 questionnaire. We would also like to thank the Director General of Health Malaysia for his permission to publish this article.

Author contributions

Conceived and designed the study: BKT, SSC, PCB. Performed the study: BKT, SSC. Analysed the data: BKT, SSC, LCC, KMC, SB, PCB. Drafted the manuscript: BKT. Revised the manuscript critically for important intellectual content and approved the final version to be published: SSC, LCC, KMC, SB, PCB.

Funding information

This study received funding from the University of Malaya under a research grant (PG057-2015A).

Compliance with ethical standards

Ethical approvals for this study was obtained from the Medical Research and Ethics Committee (MREC) Ministry of Health Malaysia (Ref. No. NMRR-14-1466-23315 [IIR] dated 7 September 2015) and Medical Ethics Committee of University Malaya Medical Centre (Ref. No. 201411-802 dated 2 November 2014).

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Fialkow PJ, Jacobson RJ, Papayannopoulou T (1977) Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 63(1):125–130CrossRefGoogle Scholar
  2. 2.
    Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 126(1):42–49CrossRefGoogle Scholar
  3. 3.
    Saussele S, Richter J, Hochhaus A, Mahon FX (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 30(8):1638–1647CrossRefGoogle Scholar
  4. 4.
    Alrabiah Z, Alhossan A, Yun S, MacDonald K, Abraham I (2016) Adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia: meta-analyses of prevalence rates by measurement method. Blood 128(22):3610CrossRefGoogle Scholar
  5. 5.
    Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 117(14):3733–3736CrossRefGoogle Scholar
  6. 6.
    Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388CrossRefGoogle Scholar
  7. 7.
    Al-Dewik NI, Morsi HM, Samara MM, Ghasoub RS, Gnanam CC, Bhaskaran SK et al (2016) Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar? Clin Med Insights Oncol 10:95–104CrossRefGoogle Scholar
  8. 8.
    Chen TC, Chen LC, Huang YB, Chang CS (2014) Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int J Clin Pharm 36(1):172–181CrossRefGoogle Scholar
  9. 9.
    Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, Nandennavar M (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86(6):471–474CrossRefGoogle Scholar
  10. 10.
    Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics. 25(6):481–496CrossRefGoogle Scholar
  11. 11.
    Jabbour E, Kantarjian H (2016) Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91(2):252–265CrossRefGoogle Scholar
  12. 12.
    Cella D, Nowinski CJ, Frankfurt O (2014) The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology. 87(3):133–147CrossRefGoogle Scholar
  13. 13.
    Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E et al (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes 11:167CrossRefGoogle Scholar
  14. 14.
    Kekale M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adher 9:1733–1740CrossRefGoogle Scholar
  15. 15.
    Chan A, Lees J, Keefe D (2014) The changing paradigm for supportive care in cancer patients. Support Care Cancer 22(6):1441–1445CrossRefGoogle Scholar
  16. 16.
    Kekale M, Soderlund T, Koskenvesa P, Talvensaari K, Airaksinen M (2016) Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study. J Adv Nurs 72(9):2196–2206CrossRefGoogle Scholar
  17. 17.
    Leader A, Benyamini N, Gafter-Gvili A, Dreyer J, Calvarysky B, Amitai A et al (2018) Effect of adherence-enhancing interventions on adherence to tyrosine kinase inhibitor treatment in chronic myeloid leukemia (TAKE-IT): a quasi-experimental pre-post intervention multicenter pilot study. Clin Lymphoma Myeloma Leuk 18(11):e449–ee61CrossRefGoogle Scholar
  18. 18.
    Moulin SM, Eutropio FJ, Souza JO, Busato FO, Olivieri DN, Tadokoro CE (2017) The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Support Care Cancer 25(3):951–955CrossRefGoogle Scholar
  19. 19.
    Moon JH, Sohn SK, Kim SN, Park SY, Yoon SS, Kim IH, Kim HJ, Kim YK, Min YH, Cheong JW, Kim JS, Jung CW, Kim DH (2012) Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol 29(2):1179–1185CrossRefGoogle Scholar
  20. 20.
    Lam MS, Cheung N (2016) Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharm Pract 22(6):741–748CrossRefGoogle Scholar
  21. 21.
    Tan BK, Tan SB, Chen LC, Chang KM, Chua SS, Balashanker S, Kamarul Jaman HNB, Edmund SC, Bee PC (2017) Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study. Patient Prefer Adher 11:1027–1034CrossRefGoogle Scholar
  22. 22.
    Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7(3):e1000251CrossRefGoogle Scholar
  23. 23.
    Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 122(6):872–884CrossRefGoogle Scholar
  24. 24.
    Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo D, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H (2018) Chronic myeloid leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 16(9):1108–1135CrossRefGoogle Scholar
  25. 25.
    Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23(3):825–836CrossRefGoogle Scholar
  26. 26.
    Coleman M (2014) Patient empowerment in the management of chronic myeloid leukemia. Clin J Oncol Nurs 18(2):E12–E18CrossRefGoogle Scholar
  27. 27.
    Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 23(6):1054–1061CrossRefGoogle Scholar
  28. 28.
    Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood. 128(1):17–23CrossRefGoogle Scholar
  29. 29.
    Michie S, van Stralen MM, West R (2011) The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci 6:42CrossRefGoogle Scholar
  30. 30.
    Hosoya K, Mochinaga S, Emoto A, Yokoo H, Tokushima H, Egoshi M, Sueoka-Aragane N, Kimura S (2015) Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia. Int J Clin Oncol 20(6):1203–1210CrossRefGoogle Scholar
  31. 31.
    Gomez-Almaguer D, Saldana-Vazquez R, Tarin-Arzaga L, Herrera-Rojas MA, Vazquez-Mellado de Larracoechea A, Cantu-Rodriguez OG et al (2016) Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure. Hematology (Amsterdam, Netherlands) 21(7):411–414Google Scholar
  32. 32.
    Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M et al (2008) Developing and evaluating complex interventions: the new Medical Research Council guidance. Bmj. 337:a1655CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medicine, Faculty of MedicineUniversity of MalayaKuala LumpurMalaysia
  2. 2.School of Pharmacy, Faculty of Health and Medical SciencesTaylor’s UniversitySubang JayaMalaysia
  3. 3.Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and HealthUniversity of Manchester, Manchester Academic Health Science CentreManchesterUK
  4. 4.Department of HematologyAmpang HospitalAmpangMalaysia
  5. 5.Ministry of Health MalaysiaPutrajayaMalaysia
  6. 6.School of PharmacyUniversity of Nottingham Malaysia CampusSemenyihMalaysia

Personalised recommendations